Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.85 USD | -1.28% | +4.90% | +26.29% |
May. 03 | Aileron Therapeutics Closes Direct Offering of Shares, Warrants | MT |
May. 01 | Transcript : Aileron Therapeutics, Inc. - Special Call |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 82.86M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -27M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.08
x | P/E ratio 2025 * |
-2.15
x | Employees | 15 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.91% |
Latest transcript on Aileron Therapeutics, Inc.
1 day | -1.28% | ||
1 week | +5.48% | ||
Current month | -15.38% | ||
1 month | -35.08% | ||
3 months | -17.74% | ||
6 months | +151.63% | ||
Current year | +26.29% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
Director of Finance/CFO | 48 | 23-09-30 | |
David Annis
CTO | Chief Tech/Sci/R&D Officer | 51 | 07-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 19-06-18 | |
Alan Musso
BRD | Director/Board Member | 62 | 23-10-30 |
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 3.85 | -1.28% | 57,080 |
24-05-15 | 3.9 | 0.00% | 20,862 |
24-05-14 | 3.9 | +0.52% | 48,242 |
24-05-13 | 3.88 | +1.57% | 17,117 |
24-05-10 | 3.82 | +4.09% | 59,933 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.29% | 66.19M | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- ALRN Stock